Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells

Yu,Chuan-Jiang; Ye,Su-Juan; Feng,Zhi-Hua; Ou,Wen-Jing; Zhou,Xi-Kun; Li,Ling-Dong; Mao,Yong-Qiu; Zhu,Wen; Wei,Yu-Quan

doi:10.3892/ol_00000132

Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells

Authors:
- Chuan-Jiang Yu
- Su-Juan Ye
- Zhi-Hua Feng
- Wen-Jing Ou
- Xi-Kun Zhou
- Ling-Dong Li
- Yong-Qiu Mao
- Wen Zhu
- Yu-Quan Wei
View Affiliations

Affiliations: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 610041 Sichuan, P.R. China
Published online on: July 1, 2010 https://doi.org/10.3892/ol_00000132
Pages: 755-760

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Lung cancer is one of the most highly malignant tumors, and a significant threat to human health. Lung cancer patients often exhibit tumor cell invasion and metastasis, which often render current treatments ineffective. Recently, the beneficial effects of low molecular weight heparin (LMWH) on cancer metastasis were reported in pre-clinical research studies. LMWH may be a potential drug for cancer therapy. However, the mechanism of LMWH on the invasion and metastasis of cancer has yet to be determined. This study investigated the effects of Fraxiparine on the proliferation, invasion and metastasis of the human lung adenocarcinoma A549 cell line. MTT assay and flow cytometry showed that Fraxiparine slightly inhibited the cell viability dose- and time-dependently, but did not arrest the A549 cells in the G1 phase nor induce early apoptosis. The transwell chamber assay showed that Fraxiparine significantly suppressed the invasion and migration of the A549 cells in vitro. Fraxiparine also markedly inhibited the adhesion of the A549 cells to Matrigel. The RT-PCR assay demonstrated that the reduction in invasion and metastasis may be related to the up-regulation of nm23-H1 and the down-regulation of the heparanase expression. Moreover, the RT-PCR assay and Western blot analysis demonstrated that down-regulation of the expression of integrin β1 and β3, as well as that of matrix metalloproteinase-2 and -9 may be responsible for the inhibition of the invasion and metastasis of A549 cells by Fraxiparine.

View Figures

View References

1	Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin. 55:10–30. 2005.
2	Rabenstein DL: Heparin and heparan sulfate: structure and function. Nat Prod Rep. 19:312–331. 2002. View Article : Google Scholar : PubMed/NCBI
3	Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, Granger C, Ohman EM and Dalen JE: Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy and safety. Chest. 119:S64–S94. 2001. View Article : Google Scholar : PubMed/NCBI
4	Akl EA, Rohilla S, Barba M, Sperati F, Terrenato I, Muti P, Bdair F and Schünemann HJ: Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review. Cancer. 113:1685–1694. 2008. View Article : Google Scholar
5	Robert F, Busby E, Marques MB, Reynolds RE and Carey DE: Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: preliminary results. Lung Cancer. 42:237–245. 2003. View Article : Google Scholar : PubMed/NCBI
6	Altinbas M, Coskun HS, Er M, Ozkan O, Eser B, Unal A, Cetin M and Soyuer S: A randomized clinical trial of combination chemotherapy with and without low-molecular-weight heparin in small cell lung cancer. J Thromb Haemost. 2:1266–1271. 2004. View Article : Google Scholar : PubMed/NCBI
7	Akl EA, van Doormaal FF, Barba M, Kamath G, Kim SY, Kuipers S, Middeldorp S, Yosuico V, Dickinson HO and Schünemann HJ: Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review. J Exp Clin Cancer Res. 27:42008. View Article : Google Scholar : PubMed/NCBI
8	Von Tempelhoff GF, Harenberg J, Niemann F, Hommel G, Kirkpatrick CJ and Heilmann L: Effect of low molecular weight heparin (Certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery: A prospective randomized double-blind trial. Int J Oncol. 16:815–824. 2000.
9	Nagy Z, Turcsik V and Blaskó G: The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 15:689–692. 2009. View Article : Google Scholar : PubMed/NCBI
10	Constantini S, Kanner A, Friedman A, Shoshan Y, Israel Z, Ashkenazi E, Gertel M, Even A, Shevach Y, Shalit M, Umansky F and Rappaport ZH: Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized double-blind study. J Neurosurg. 94:918–921. 2001. View Article : Google Scholar : PubMed/NCBI
11	Kakkar AK, Levine MN, Kadziola Z, Lemoine NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M and Williamson RC: Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the Fragmin Advanced Malignancy Outcome Study (FAMOUS). J Clin Oncol. 22:1944–1948. 2004. View Article : Google Scholar : PubMed/NCBI
12	Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van Tienhoven G and Büller HR: The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
13	Kuderer NM, Ortel TL and Francis CW: Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol. 27:4902–4911. 2009. View Article : Google Scholar : PubMed/NCBI
14	Kragh M, Binderup L, Vig Hjarnaa PJ, Bramm E, Johansen KB and Frimundt Petersen C: Non-anti-coagulant heparin inhibits metastasis but not primary tumor growth. Oncol Rep. 14:99–104. 2005.PubMed/NCBI
15	Ludwig RJ, Boehme B, Podda M, Henschler R, Jager E, Tandi C, Boehncke WH, Zollner TM, Kaufmann R and Gille J: Endothelial p-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 64:2743–2750. 2004. View Article : Google Scholar : PubMed/NCBI
16	Mellor P, Harvey JR, Murphy KJ, Pye D, O’Boyle G, Lennard TWJ, Kirby JA and Ali S: Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer. 97:761–768. 2007. View Article : Google Scholar : PubMed/NCBI
17	Smorenburg SM, Vink R, Otten HM, Swaneveld F and Büller HR: The effects of vitamin K antagonists on survival of patients with malignancy: a systematic analysis. Thromb Haemost. 86:1586–1587. 2001.PubMed/NCBI
18	Niers TM, Klerk CP, DiNisio M, van Noorden CJ, Büller HR, Reitsma PH and Richel DJ: Mechanisms of heparin-induced anti-cancer activity in experimental cancer models. Crit Rev Oncol Hematol. 61:195–207. 2007. View Article : Google Scholar : PubMed/NCBI
19	Takahashi H, Ebihara S, Okazaki T and Yamaya M: A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumor angiogenesis and heparanase activity. Br J Pharmacol. 146:333–343. 2005. View Article : Google Scholar
20	Mousa SA and Petersen LJ: Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 102:258–267. 2009.PubMed/NCBI
21	Hostettler N, Naggi A, Torri G, Ishai-Michaeli R, Casu B, Vlodavsky I and Borsig L: P-selectin- and heparanase-dependent antimetastatic activity of non-anticoagulant heparins. FASEB J. 21:3562–3572. 2007. View Article : Google Scholar : PubMed/NCBI
22	Stevenson JL, Choi SH and Varki A: Differential metastasis inhibition by clinically relevant levels of heparins – correlation with selectin inhibition, not antithrombotic activity. Clin Cancer Res. 11:7003–7011. 2005.PubMed/NCBI
23	Vlodavsky I, Goldshmidt O, Zcharia E, Atzmon R, Rangini-Guatta Z, Elkin M, Peretz T and Friedmann Y: Mammalian heparanase: involvement in cancer metastasis, angiogenesis and normal development. Semin Cancer Biol. 12:121–129. 2002. View Article : Google Scholar : PubMed/NCBI
24	Sasaki M, Ito T, Kashima M and Miura M: Erythromycin and clarithromycin modulation of growth factor-induced expression of heparanase mRNA on human lung cancer cells in vitro. Mediators Inflamm. 10:259–267. 2001. View Article : Google Scholar : PubMed/NCBI
25	Edovitsky E, Elkin M, Zcharia E, Peretz T and Vlodavsky I: Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst. 96:1219–1230. 2004. View Article : Google Scholar : PubMed/NCBI
26	Joyce JA, Freeman C, Meyer-Morse N, Parish CR and Hanahan D: A functional heparan sulfate mimetic implicates both heparanase and heparan sulfate in tumor angiogenesis and invasion in a mouse model of multistage cancer. Oncogene. 24:4037–4051. 2005. View Article : Google Scholar : PubMed/NCBI
27	Uno F, Fujiwara T, Takata Y, Ohtani S, Katsuda K, Takaoka M, Ohkawa T, Naomoto Y, Nakajima M and Tanaka N: Antisense-mediated suppression of human heparanase gene expression inhibits pleural dissemination of human cancer cells. Cancer Res. 61:7855–7860. 2001.PubMed/NCBI
28	Steeg PS, Bevilacqua G, Kopper L, Thorgeirsson UP, Talmadge JE, Liotta LA and Sobel ME: Evidence for a novel gene associated with low tumor metastatic potential. J Natl Cancer Inst. 80:200–204. 1988. View Article : Google Scholar : PubMed/NCBI
29	Kawakubo Y, Sato Y, Koh T, Kono H and Kameya T: Expression of nm23 protein in pulmonary adenocarcinomas: inverse correlation to tumor progression. Lung Cancer. 17:103–113. 1997. View Article : Google Scholar : PubMed/NCBI
30	Steeg PS, Ouatas T, Halverson D, Palmieri D and Salerno M: Metastasis suppressor genes: basic biology and potential clinical use. Clin Breast Cancer. 4:51–62. 2003. View Article : Google Scholar : PubMed/NCBI
31	Ma W, Chen J, Xue X, Wang Z, Liu H, Wang T, Bai Y, Tang SC and Zhou Q: Alteration in gene expression profile and biological behavior in human lung cancer cell line NL9980 by nm23-H1 gene silencing. Biochem Biophys Res Commun. 371:425–430. 2008. View Article : Google Scholar : PubMed/NCBI
32	Humphries MJ: Integrin structure. Biochem Soc Trans. 28:311–339. 2000. View Article : Google Scholar
33	Giancotti FG and Ruoslahti E: Integrin signaling. Science. 285:1028–1032. 1999. View Article : Google Scholar : PubMed/NCBI
34	Miranti CK and Brugge JS: Sensing the environment: a historical perspective on integrin signal transduction. Nat Cell Biol. 4:E83–E90. 2002. View Article : Google Scholar : PubMed/NCBI
35	Westermarck J and Kähäri VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:781–792. 1999.PubMed/NCBI
36	Zeng ZS, Cohen AM and Guillem JG: Loss of basement membrane type IV collagen is associated with increased expression of metalloproteinases 2 and 9 (MMP-2 and MMP-9) during human colorectal tumorigenesis. Carcinogenesis. 20:749–755. 1999. View Article : Google Scholar : PubMed/NCBI
37	Fareed J, Leong WL, Hoppensteadt DA, Jeske WP, Walenga J, Wahi R and Bick RL: Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost. 30:703–713. 2004. View Article : Google Scholar : PubMed/NCBI
38	Deepa PR and Varalakshmi P: The cytoprotective role of a low-molecular-weight heparin fragment studied in an experimental model of glomerulotoxicity. Eur J Pharmacol. 478:199–205. 2003. View Article : Google Scholar : PubMed/NCBI